Table of Contents
1.Overview and Scope
1.1.Research goal & scope
1.2.Research assumptions
1.3.Research Methodology
1.3.1.Primary data sources
1.3.2.Secondary data sources
1.4.Key take-away
1.5.Stakeholders
2.Executive Summary
2.1.Market Definition
2.2.Market Segmentation
3.Sleep Disorder Market Insights
3.1.Sleep Disorder – Industry snapshot
3.2.Sleep Disorder - Ecosystem analysis
3.3.Sleep Disorder Market Dynamics
3.3.1.Sleep Disorder – Market Forces
3.3.1.1.Sleep Disorder Market Driver Analysis
3.3.1.2.Sleep Disorder Market Restraint/Challenges analysis
3.3.1.3.Sleep Disorder Market Opportunity Analysis
3.4.Industry analysis - Porter's five force
3.4.1.Bargaining power of supplier
3.4.2.Bargaining power of buyer
3.4.3.Threat of substitute
3.4.4.Threat of new entrant
3.4.5.Degree of competition
3.5.Sleep Disorder Market PEST Analysis
3.6.Sleep Disorder Market Value Chain Analysis
3.7.Sleep Disorder Industry Trends
3.8.Competitive Ranking Analysis, 2017
4.Sleep Disorder Market Size and Forecast by Disorder, 2018-2026
4.1.Key Findings
4.2.Insomnia
4.3.Hypersomnia
4.3.1.Insufficient Sleep Syndrome
4.3.2.Narcolepsy
4.4.Sleep Apnea
4.5.Sleep Breathing Disorders
4.6.Circadian Rhythm Disorders
4.7.Parasomnia
4.7.1.Sleep Eating Disorder
4.7.2.Sleep Terror
4.7.3.REM Sleep Behavior Disorder
4.8.Sleep Movement Disorders
4.8.1.Restless Leg Syndrome
4.8.2.Sleep Leg Cramps
5.Sleep Disorder Market Size and Forecast by Device, 2018-2026
5.1.Key Findings
5.2.Sleep Apnea Devices
5.3.Sleep Laboratories
5.4.Mattresses & Pillows
6. Sleep Disorder Market Size and Forecast by Treatment, 2018-2026
6.1.Key Findings
6.2.Psychiatric Treatment
6.3.Behavioral Treatment
6.4.Cognitive Behavioral Therapy
6.5.Medication Therapy
6.5.1.Prescription Drugs
6.5.2.OTC Drugs
6.5.3.Herbal Drugs
7.Sleep Disorder Market Size and Forecast by Region, 2018-2026
7.1.Key Findings
7.2.North America
7.2.1.U.S.
7.2.2.Canada
7.3.Europe
7.3.1.Germany
7.3.2.UK
7.3.3.France
7.3.4.Italy
7.3.5.Spain
7.3.6.Belgium
7.3.7.Russia
7.3.8.Netherlands
7.3.9.Rest of Europe
7.4.Asia-Pacific
7.4.1.China
7.4.2.India
7.4.3.Japan
7.4.4.Korea
7.4.5.Singapore
7.4.6.Malaysia
7.4.7.Indonesia
7.4.8.Thailand
7.4.9.Philippines
7.4.10.Rest of Asia-Pacific
7.5.Latin America
7.5.1.Brazil
7.5.2.Mexico
7.5.3.Argentina
7.5.4.Rest of LATAM
7.6.Middle East & Africa
7.6.1.UAE
7.6.2.Saudi Arabia
7.6.3.South Africa
7.6.4.Rest of MEA
8.Company Profiles
8.1.GlaxoSmithKline Plc
8.1.1.Overview
8.1.2.Financials
8.1.3.Product Benchmarking
8.1.4.Recent Developments
8.2.Becton Dickson and Company
8.2.1.Overview
8.2.2.Financials
8.2.3.Product Benchmarking
8.2.4.Recent Developments
8.3.Cardinal Health
8.3.1.Overview
8.3.2.Financials
8.3.3.Product Benchmarking
8.3.4.Recent Developments
8.4.Natus Medical Incorporated.
8.4.1.Overview
8.4.2.Financials
8.4.3.Product Benchmarking
8.4.4.Recent Developments
8.5.Takeda Pharmaceutical Company Limited
8.5.1.Overview
8.5.2.Financials
8.5.3.Product Benchmarking
8.5.4.Recent Developments
8.6.Koninklijke Philips N.V.
8.6.1.Overview
8.6.2.Financials
8.6.3.Product Benchmarking
8.6.4.Recent Developments
8.7.Teva Pharmaceutical Industries Ltd.
8.7.1.Overview
8.7.2.Financials
8.7.3.Product Benchmarking
8.7.4.Recent Developments